359 related articles for article (PubMed ID: 33380303)
1. Immune Checkpoint Inhibitors and Neurotoxicity.
Zhao Z; Zhang C; Zhou L; Dong P; Shi L
Curr Neuropharmacol; 2021; 19(8):1246-1263. PubMed ID: 33380303
[TBL] [Abstract][Full Text] [Related]
2. Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials.
Bruna J; Argyriou AA; Anastopoulou GG; Alemany M; Nadal E; Kalofonou F; Piulats JM; Simó M; Velasco R; Kalofonos HP
J Peripher Nerv Syst; 2020 Jun; 25(2):171-177. PubMed ID: 32166812
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
4. Peripheral nervous system adverse events associated with immune checkpoint inhibitors.
Rossi S; Gelsomino F; Rinaldi R; Muccioli L; Comito F; Di Federico A; De Giglio A; Lamberti G; Andrini E; Mollica V; D'Angelo R; Baccari F; Zenesini C; Madia P; Raschi E; Cortelli P; Ardizzoni A; Guarino M
J Neurol; 2023 Jun; 270(6):2975-2986. PubMed ID: 36800019
[TBL] [Abstract][Full Text] [Related]
5. Neurological adverse events of immune checkpoint inhibitors: An update of clinical presentations, diagnosis, and management.
Farina A; Villagrán-García M; Honnorat J
Rev Neurol (Paris); 2023 Jun; 179(5):506-515. PubMed ID: 36934022
[TBL] [Abstract][Full Text] [Related]
6. [Chinese expert consensus on diagnosis and treatment of neurologic immune-related adverse events associated with immune checkpoint inhibitors (2022 edition)].
;
Zhonghua Zhong Liu Za Zhi; 2022 Sep; 44(9):935-941. PubMed ID: 36164694
[TBL] [Abstract][Full Text] [Related]
7. Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition.
Pan PC; Haggiagi A
Curr Oncol Rep; 2019 Nov; 21(12):108. PubMed ID: 31776691
[TBL] [Abstract][Full Text] [Related]
8. Neurological toxicities associated with immune-checkpoint inhibitors.
Touat M; Talmasov D; Ricard D; Psimaras D
Curr Opin Neurol; 2017 Dec; 30(6):659-668. PubMed ID: 28938341
[TBL] [Abstract][Full Text] [Related]
9. CNS and PNS manifestation in immune checkpoint inhibitors: A systematic review.
Khan E; Shrestha AK; Elkhooly M; Wilson H; Ebbert M; Srivastava S; Wen S; Rollins S; Sriwastava S
J Neurol Sci; 2022 Jan; 432():120089. PubMed ID: 34942546
[TBL] [Abstract][Full Text] [Related]
10. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature.
Cuzzubbo S; Javeri F; Tissier M; Roumi A; Barlog C; Doridam J; Lebbe C; Belin C; Ursu R; Carpentier AF
Eur J Cancer; 2017 Mar; 73():1-8. PubMed ID: 28064139
[TBL] [Abstract][Full Text] [Related]
11. Neurological immune-related adverse events associated with immune checkpoint inhibitors: A review of the literature.
Fan S; Ren H; Zhao L; Yin J; Feng G; Wang J; Guan H
Asia Pac J Clin Oncol; 2020 Dec; 16(6):291-298. PubMed ID: 32893999
[TBL] [Abstract][Full Text] [Related]
12. Neurotoxicities associated with immune checkpoint inhibitor therapy.
Duong SL; Barbiero FJ; Nowak RJ; Baehring JM
J Neurooncol; 2021 Apr; 152(2):265-277. PubMed ID: 33454891
[TBL] [Abstract][Full Text] [Related]
13. Neurologic complications of immune checkpoint inhibitors.
Haugh AM; Probasco JC; Johnson DB
Expert Opin Drug Saf; 2020 Apr; 19(4):479-488. PubMed ID: 32126176
[No Abstract] [Full Text] [Related]
14. Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors.
Zhou Y; Li H
Front Neurosci; 2023; 17():1227049. PubMed ID: 37456998
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.
Villagrán-García M; Velasco R
Neurol Sci; 2022 Apr; 43(4):2339-2361. PubMed ID: 35175441
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of immune checkpoint inhibitor-related neurological adverse events and association with anti-neuronal autoantibodies.
Salim A; Tapia Rico G; Shaikh A; Brown MP
Expert Opin Biol Ther; 2021 Sep; 21(9):1237-1251. PubMed ID: 33645372
[No Abstract] [Full Text] [Related]
17. Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors.
Vilariño N; Bruna J; Kalofonou F; Anastopoulou GG; Argyriou AA
Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32796758
[TBL] [Abstract][Full Text] [Related]
18. Expert Perspective: Immune Checkpoint Inhibitors and Rheumatologic Complications.
Cappelli LC; Bingham CO
Arthritis Rheumatol; 2021 Apr; 73(4):553-565. PubMed ID: 33186490
[TBL] [Abstract][Full Text] [Related]
19. Patterns of neurological adverse events among a retrospective cohort of patients receiving immune checkpoint inhibitors.
Hunting JC; Faucheux AT; Price SN; Elko CA; Quattlebaum A; Bloomer C; Olson E; Petty WJ; Lycan TW
Immunotherapy; 2024 Apr; 16(6):381-390. PubMed ID: 38197144
[TBL] [Abstract][Full Text] [Related]
20. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]